Novartis Benefits From Lack of Generic Challenge

Novartis Benefits From Lack of Generic Challenge Play

April 24 (Bloomberg) -- Bloomberg's Jonathan Ferro reports that Novartis AG saw first-quarter profit rise 7 percent as a competitor's generic version of the company’s second-best-selling medicine failed to reach the market. He speaks on Bloomberg Television's "On The Move."

  • On Air Now

    Market Makers Watch Now

  • Next

    Money Clip

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus